- Home
- ACLX vs FHI Comparison
ACLX vs FHI Comparison
Compare ACLX & FHI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ACLX
- FHI
- Stock Information
- Founded
- ACLX 2015
- FHI 1955
- Country
- ACLX United States
- FHI United States
- Employees
- ACLX N/A
- FHI N/A
- Industry
- ACLX Biotechnology: Pharmaceutical Preparations
- FHI Investment Managers
- Sector
- ACLX Health Care
- FHI Finance
- Exchange
- ACLX Nasdaq
- FHI Nasdaq
- Market Cap
- ACLX 4.4B
- FHI 4.0B
- IPO Year
- ACLX 2022
- FHI N/A
- Fundamental
- Price
- ACLX $88.62
- FHI $53.24
- Analyst Decision
- ACLX Strong Buy
- FHI Buy
- Analyst Count
- ACLX 12
- FHI 7
- Target Price
- ACLX $114.75
- FHI $47.86
- AVG Volume (30 Days)
- ACLX 515.6K
- FHI 653.5K
- Earning Date
- ACLX 11-06-2025
- FHI 10-30-2025
- Dividend Yield
- ACLX N/A
- FHI 2.57%
- EPS Growth
- ACLX N/A
- FHI 53.50
- EPS
- ACLX N/A
- FHI 4.52
- Revenue
- ACLX $56,979,000.00
- FHI $1,681,523,000.00
- Revenue This Year
- ACLX N/A
- FHI $7.41
- Revenue Next Year
- ACLX $210.71
- FHI $4.73
- P/E Ratio
- ACLX N/A
- FHI $11.70
- Revenue Growth
- ACLX N/A
- FHI 5.55
- 52 Week Low
- ACLX $47.86
- FHI $35.05
- 52 Week High
- ACLX $107.37
- FHI $54.42
- Technical
- Relative Strength Index (RSI)
- ACLX 68.46
- FHI 58.17
- Support Level
- ACLX $83.33
- FHI $51.22
- Resistance Level
- ACLX $89.31
- FHI $53.09
- Average True Range (ATR)
- ACLX 2.66
- FHI 0.75
- MACD
- ACLX 0.42
- FHI -0.00
- Stochastic Oscillator
- ACLX 63.77
- FHI 91.99
About ACLX Arcellx Inc.
Arcellx Inc a clinical-stage biotechnology company reimagining cell therapy through the development of immunotherapies for patients with cancer and other incurable diseases. Its pipeline includes Multiple Myeloma, Acute Myeloid Leukemia, Non-Oncology, and Solid Tumors.
About FHI Federated Hermes Inc.
Federated Hermes provides asset-management services for institutional and individual investors. The firm had $843.7 billion in managed assets at the end of June 2025, composed of equity (10%), multi-asset (less than 1%), fixed-income (12%), alternative (2%), and money market (75%) funds. The firm's cash-management operations are expected to generate around 52% of Federated's revenue this year, compared with 29%, 11%, and 8%, respectively, for the equity, fixed-income, and alternatives/multi-asset/other operations. The company's products are distributed via trust banks, wealth managers, and retail broker/dealers (67% of AUM), institutional investors (26%), and international clients (7%).